articleOpen MINDJan 1, 2022Closed access

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

LJLuke, Jason JRPRutkowski, PiotrQPQueirolo, PaolaDVDel Vecchio, MicheleEAet al

Abstract

No abstract available for this paper.

Citation impact

443
total citations
FWCI
45.86
Percentile
100%
References
19
Citations per year

Authors

6
  • LJ
    Luke, Jason JCorresponding
  • RP
    Rutkowski, Piotr
  • QP
    Queirolo, Paola
  • DV
    Del Vecchio, Michele
  • EA
    et al

Topics & keywords

Topics
Keywords
  • Medicine
  • Pembrolizumab
  • Clinical endpoint
  • Placebo
  • Interim analysis
  • Population
  • Internal medicine
  • Melanoma
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.